Page 152 - NobleCon21

Health Care
Date November 20, 2025 Health Care
52wk High $63.45
52wk Low $2.40 Silexion Therapeutics Corp SLXN $2.49
The Goldyne Savad Inst. of Gene Therapy
Jerusalem, N/A 9112001

(USD - in millions) silexion.com
Market Cap 1.4
Enterprise 4.7
Basic Shares Out. 0.56 COMPANY OVERVIEW
Float 0.43
Institutional Holdings 5.15% Detailed Analysis:Channelchek.com
Short Interest 0.15
Avg. 90-Day Volume 0.47 Silexion Therapeutics is a clinical stage, oncology-focused
biotechnology company developing innovative treatments for
aggressive solid tumor cancers of high unmet need driven by mutated
KRAS proteins. Silexion develops RNA silencing therapies to abolish
EPS Data KRAS expression by silencing messenger RNA (mRNA). Silexion’s first
generation product was validated in a Phase 2a clinical trial
2022 2023 2024 demonstrating survival benefit. The Company had developed a second
CQ1 N/A N/A (734.40) generation product (SIL204) designed for enhanced delivery, better
CQ2 N/A N/A N/A stability, and broad antitumor activity. Silexion plans to enter SIL204
into Phase 2 clinical development in 2026.
CQ3 N/A N/A (274.05)
CQ4 N/A N/A (311.40)
CY N/A N/A (395.40) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) -32.37
ROE (ttm) NM
Debt-to-Total Cap. (mrq) 894.62
Fiscal Year End 31-Dec

The Goldyne SJerusalem N/A 9112001

Key Executives
CEO: Hadar, Ilan
CFO: Hadar, Mirit
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures